COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patients.
COVID-19
Dementia
Mortality
Prognostic factors
SARS-CoV-2
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
10 04 2021
10 04 2021
Historique:
received:
05
02
2021
accepted:
26
03
2021
entrez:
11
4
2021
pubmed:
12
4
2021
medline:
24
4
2021
Statut:
epublish
Résumé
There is limited evidence on the characteristics and outcome of patients with dementia hospitalised for novel coronavirus infection (COVID-19). We conducted a prospective study in 2 gerontologic COVID units in Paris, France, from March 14, 2020, to May 7, 2020. Patients with dementia hospitalised for confirmed COVID-19 infection were systematically enrolled. A binary logistic regression analysis was performed to identify factors associated with mortality at 21 days. We included 125 patients. Median age was 86 (IQI 82-90); 59.4% were female. Most common causes of dementia were Alzheimer's disease, mixed dementia and vascular dementia. 67.2% had ≥ 2 comorbidities; 40.2% lived in a long-term care facility. The most common symptoms at COVID-19 onset were confusion and delirium (82.4%), asthenia (76.8%) and fever (72.8%) before polypnea (51.2%) and desaturation (50.4%). Falls were frequent at the initial phase of the disease (35.2%). The fatality rate at 21 days was 22.4%. Chronic kidney disease and CRP at admission were independent factors of death. Persisting confusion, mood and behavioural disorders were observed in survivors (19.2%). COVID-19 in demented individuals is associated with severe outcome in SARS-CoV-2 infection and is characterised by specific clinical features and complications, with confusion and delirium at the forefront. COVID-19 testing should be considered in front of any significant change from baseline.
Sections du résumé
BACKGROUND
There is limited evidence on the characteristics and outcome of patients with dementia hospitalised for novel coronavirus infection (COVID-19).
METHOD
We conducted a prospective study in 2 gerontologic COVID units in Paris, France, from March 14, 2020, to May 7, 2020. Patients with dementia hospitalised for confirmed COVID-19 infection were systematically enrolled. A binary logistic regression analysis was performed to identify factors associated with mortality at 21 days.
RESULTS
We included 125 patients. Median age was 86 (IQI 82-90); 59.4% were female. Most common causes of dementia were Alzheimer's disease, mixed dementia and vascular dementia. 67.2% had ≥ 2 comorbidities; 40.2% lived in a long-term care facility. The most common symptoms at COVID-19 onset were confusion and delirium (82.4%), asthenia (76.8%) and fever (72.8%) before polypnea (51.2%) and desaturation (50.4%). Falls were frequent at the initial phase of the disease (35.2%). The fatality rate at 21 days was 22.4%. Chronic kidney disease and CRP at admission were independent factors of death. Persisting confusion, mood and behavioural disorders were observed in survivors (19.2%).
CONCLUSION
COVID-19 in demented individuals is associated with severe outcome in SARS-CoV-2 infection and is characterised by specific clinical features and complications, with confusion and delirium at the forefront. COVID-19 testing should be considered in front of any significant change from baseline.
Identifiants
pubmed: 33838684
doi: 10.1186/s13195-021-00820-9
pii: 10.1186/s13195-021-00820-9
pmc: PMC8035874
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Neurology. 2020 Sep 22;95(12):e1754-e1759
pubmed: 32546655
JAMA. 2010 Jul 28;304(4):443-51
pubmed: 20664045
Age Ageing. 2020 Jul 1;49(4):523-524
pubmed: 32315386
Scand J Public Health. 2002;30(1):54-61
pubmed: 11928835
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Alzheimers Dement (Amst). 2020 Nov 14;12(1):e12114
pubmed: 33225041
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
J Alzheimers Dis. 2020;78(4):1775-1782
pubmed: 33285638
Ann Clin Transl Neurol. 2020 Aug;7(8):1450-1452
pubmed: 32433817
J Am Geriatr Soc. 2020 Nov;68(11):2440-2446
pubmed: 32835425
J Alzheimers Dis. 2020;78(2):537-541
pubmed: 33074240
J Am Geriatr Soc. 2020 Jul;68(7):1382-1384
pubmed: 32383778
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
JAMA. 2020 Dec 8;324(22):2292-2300
pubmed: 33180097
J Am Geriatr Soc. 2020 Dec;68(12):2735-2743
pubmed: 33045106
Neurology. 2021 Jan 26;96(4):e575-e586
pubmed: 33020166
J Nutr Health Aging. 2020;24(6):560-562
pubmed: 32510106
EClinicalMedicine. 2020 Sep;26:100490
pubmed: 32838241
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Neurology. 2011 Jul 19;77(3):212-8
pubmed: 21753171
Neurocrit Care. 2020 Jul 13;:
pubmed: 32661794
J Am Geriatr Soc. 2020 Jul;68(7):E36-E37
pubmed: 32343395
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
J Alzheimers Dis. 2020;78(4):1367-1372
pubmed: 33074239
Intern Emerg Med. 2014 Mar;9(2):195-200
pubmed: 24048917
Eur Arch Otorhinolaryngol. 2021 Jan 16;:
pubmed: 33452919
Neurology. 2019 Feb 12;92(7):e700-e709
pubmed: 30651382
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Z Gerontol Geriatr. 2004 Feb;37(1):27-32
pubmed: 14991293
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Infection. 2021 Mar 1;:
pubmed: 33646505
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-2230
pubmed: 32687551
Lancet. 2014 Mar 8;383(9920):911-22
pubmed: 23992774
Aging Clin Exp Res. 2015 Aug;27(4):523-31
pubmed: 25556562